ERBB2 and breast cancer: Zucchini et al. evaluated metabolic changes with FDG PET/CT after receiving NAC in 60 early or locally advanced breast cancer patients, showing that early metabolic non-response was always related to histological non-responders and poor prognosis in ER-positive/HER2-negative patients [29].